Stroke:脑出血急性期进一步强化降压治疗或利于临床预后

2013-05-28 Stroke dxy

急性脑出血患者的降压治疗时常规急性期处理的一部分。然而,降压治疗与临床预后的关系尚不明确。来自日本的Yuki Sakamoto等人研究了这方面的问题,在线发表在2013年5月23日的stroke杂志上,研究结果显示:脑出血急性期进一步强化降压治疗或利于临床预后。 该研究纳入脑出血超急性期(发病3小时内)初始收缩压超过180 mm Hg的患者。所有患者接受静脉降压治疗,基于预订的目标,血压降至1

急性脑出血患者的降压治疗时常规急性期处理的一部分。然而,降压治疗与临床预后的关系尚不明确。来自日本的Yuki Sakamoto等人研究了这方面的问题,在线发表在2013年5月23日的stroke杂志上,研究结果显示:脑出血急性期进一步强化降压治疗或利于临床预后。

该研究纳入脑出血超急性期(发病3小时内)初始收缩压超过180 mm Hg的患者。所有患者接受静脉降压治疗,基于预订的目标,血压降至120至160 mm Hg之间。在初始两小时内每15分钟测一次血压,在随后22小时内每小时测一次(总共测量30次)、平均收缩压为30次测量的收缩压的平均值,使用多因素logistic回归分析评价平均收缩压与神经功能恶化(定义为Glasgow昏迷评分下降超过两分,NIHSS评分增加超过4分)、血肿体积扩大(增加超过33%)及不良预后(3个月后改良Rankin指数4到6分)。

纳入的211例患者中,81例为女性患者,平均年龄为65岁(四分位间距为58-74岁),发病时初始NIHSS评分为13分(范围为8到17分),17例(8%)患者显示神经功能恶化,36例(17%)显示血肿扩大,87例(41%)显示出现不良预后。多元回归分析显示,在调整其他预测因素后,降压后的平均收缩压是神经功能恶化(平均收缩压每增加 10 mm Hg的优势比为4.45,95%可信区间为2.03–9.74),血肿扩大(1.86; 1.09–3.16)和不良预后(2.03; 1.24–3.33)的的独立危险因素。

超急性脑出血患者在使用标准降压治疗后获得的平均收缩压与临床不良预后相关。进一步增强降压治疗或可改善临床预后。

Systolic Blood Pressure After Intravenous Antihypertensive Treatment and Clinical Outcomes in Hyperacute Intracerebral Hemorrhage: The Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study.
BACKGROUND AND PURPOSE
Blood pressure (BP) lowering is often conducted as part of general acute management in patients with acute intracerebral hemorrhage. However, the relationship between BP after antihypertensive therapy and clinical outcomes is not fully known.
METHODS
Hyperacute (<3 hours from onset) intracerebral hemorrhage patients with initial systolic BP (SBP) >180 mm Hg were included. All patients received intravenous antihypertensive treatment, based on predefined protocol to lower and maintain SBP between 120 and 160 mm Hg. BPs were measured every 15 minutes during the initial 2 hours and every 60 minutes in the next 22 hours (a total of 30 measurements). The mean achieved SBP was defined as the mean of 30 SBPs, and associations between the mean achieved SBP and neurological deterioration (≥2 points' decrease in Glasgow Coma Score or ≥4 points' increase in National Institutes of Health Stroke Scale score), hematoma expansion (>33% increase), and unfavorable outcome (modified Rankin Scale score 4-6 at 3 months) were assessed with multivariate logistic regression analyses.
RESULTS
Of the 211 patients (81 women, median age 65 [interquartile range, 58-74] years, and median initial National Institutes of Health Stroke Scale score 13 [8-17]) enrolled, 17 (8%) showed neurological deterioration, 36 (17%) showed hematoma expansion, and 87 (41%) had an unfavorable outcome. On multivariate regression analyses, mean achieved SBP was independently associated with neurological deterioration (odds ratio, 4.45; 95% confidence interval, 2.03-9.74 per 10 mm Hg increment), hematoma expansion (1.86; 1.09-3.16), and unfavorable outcome (2.03; 1.24-3.33) after adjusting for known predictive factors.
CONCLUSIONS
High achieved SBP after standardized antihypertensive therapy in hyperacute intracerebral hemorrhage was independently associated with poor clinical outcomes. Aggressive antihypertensive treatment may ameliorate clinical outcomes.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678247, encodeId=fd4716e8247fc, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Sat Nov 02 23:57:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291793, encodeId=31b41291e93be, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360831, encodeId=a4771360831b6, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419056, encodeId=8a301419056ef, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534692, encodeId=6568153469264, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
    2013-11-02 feifers
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678247, encodeId=fd4716e8247fc, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Sat Nov 02 23:57:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291793, encodeId=31b41291e93be, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360831, encodeId=a4771360831b6, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419056, encodeId=8a301419056ef, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534692, encodeId=6568153469264, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678247, encodeId=fd4716e8247fc, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Sat Nov 02 23:57:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291793, encodeId=31b41291e93be, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360831, encodeId=a4771360831b6, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419056, encodeId=8a301419056ef, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534692, encodeId=6568153469264, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1678247, encodeId=fd4716e8247fc, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Sat Nov 02 23:57:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291793, encodeId=31b41291e93be, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360831, encodeId=a4771360831b6, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419056, encodeId=8a301419056ef, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534692, encodeId=6568153469264, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1678247, encodeId=fd4716e8247fc, content=<a href='/topic/show?id=12025231333' target=_blank style='color:#2F92EE;'>#急性期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52313, encryptionId=12025231333, topicName=急性期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b8027680692, createdName=feifers, createdTime=Sat Nov 02 23:57:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291793, encodeId=31b41291e93be, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360831, encodeId=a4771360831b6, content=<a href='/topic/show?id=87fe98146d7' target=_blank style='color:#2F92EE;'>#降压治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98146, encryptionId=87fe98146d7, topicName=降压治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419056, encodeId=8a301419056ef, content=<a href='/topic/show?id=e051501461d' target=_blank style='color:#2F92EE;'>#强化降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50146, encryptionId=e051501461d, topicName=强化降压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6c3470765, createdName=fengxx, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534692, encodeId=6568153469264, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Thu May 30 00:57:00 CST 2013, time=2013-05-30, status=1, ipAttribution=)]

相关资讯

Stroke:血管内卒中治疗合用替罗非班增加脑出血风险

使用IIb/IIIa抑制剂替罗非班与严重出血并发症和机械性取栓后转归的相关性尚不清楚。为此,德国Heidelberg大学神经科的Lars Kellert博士等人进行了一项研究,研究结果在线发表在2013年3 月5日的Stroke杂志上。研究结果显示:血管内卒中治疗,联合使用糖蛋白IIb-IIIa抑制剂替罗非班与致死性颅内出血风险增加及转归差相关。研究中纳入了前瞻性收集的连续病例,这些病例是在200

Circulation:卒中和脑出血对感染性心内膜炎有负面影响

  西班牙一项研究表明,中重度缺血性卒中和脑出血对感染性心内膜炎(IE)转归具有显著负面影响。研究进一步提示了早期适当地抗菌治疗的重要性,且应考虑暂时中断抗凝治疗。论文于5月6日在线发表于《循环》(Circulation)。   此项研究共纳入1345例次左侧IE发作,并对前瞻性采集的资料进行了回顾性分析。利用Cox回归模型分析神经系统并发症和相关死亡的预测变量。   结果显示,共有340例患

ANN NEUROL:防止脑出血新方法

  复旦大学医学神经生物学国家重点实验室、脑科学研究院赵冰樵教授研究团队,在国家自然科学基金、上海市浦江人才计划、教育部博士点基金和国家973项目等经费支持下,经3年艰苦攻关,首次发现一种在特定细胞内合成并提取出的物质“重组ADAMTS13”可以有效减少溶栓治疗脑中风时引起的脑出血,该成果有望为脑中风患者接受更安全有效的治疗带来新的契机。相关论文12月31日在线发表在国际神经科学领域权威期刊《神经

Lancet Neurol:CTA上的斑点征可以预测ICH血肿扩大

背景:脑出血(ICH)早期血肿扩大程度严重影响患者临床预后。止血治疗可以减少血肿扩大,但却未能改善许多患者的临床预后。能否准确分辨血肿扩大的高危患者成为改善预后的关键。本研究为了证明CT血管造影(CTA)能否预测血肿扩大。方法:这项名为PREDICT(使用对比bolus CT预测脑出血血肿的扩大)的研究是一项多中心的前瞻性观察队列研究。研究者招募了年龄在18岁(含)以上的ICH病人,脑出血量小于1

Neurology:重度饮酒使脑出血发病提前14年

               每天饮酒3次或更多的重度饮酒者患脑出血的风险增加,他们发病的年龄比那些不饮酒的患者要早,根据Neurolog最新的一项研究指出。[Neurology 2012 Sep 11;79(11):1109-15]   &n

Neurology:常服抗抑郁药或增加脑出血风险

  美国《神经病学》杂志网络版刊登一项报告说,经常服用某类广泛使用的抗抑郁药将增加服用者脑出血的风险。研究人员提醒已存在此类风险的患者可考虑使用其他类型药物。   加拿大安大略西部大学研究人员报告说,他们对包括50万名对象的16项研究汇总分析后发现,与不服药者相比,日常服用选择性血清再吸收抑制剂类抗抑郁药者颅内出血的风险高50%,出现脑溢血的风险高40%。   选择性血清再吸收抑制剂是一类抗抑